Table 3.
Diagnostic performance the radiomic signature and radiomic nomogram of low-dose CT and standard-dose CT, and Lung-RADS for differentiating adenocarcinomas from benign nodules in the primary and validation cohorts.
| AUC (95% CI) | Sensitivity | Specificity | Accuracy | PPV | NPV | |
|---|---|---|---|---|---|---|
| Primary cohort | ||||||
| Radiomic signature of low-dose CT |
0.915 (0.859–0.972) |
0.860 (43/50) |
0.854 (41/48) |
0.857 (84/98) |
0.860 (43/50) |
0.854 (41/48) |
| Radiomic nomogram of low-dose CT |
0.919 (0.861–0.977) |
0.920 (46/50) |
0.854 (41/48) |
0.888 (87/98) |
0.868 (46/53) |
0.911 (41/45) |
| Radiomic signature of standard-dose CT |
0.898 (0.833–0.963) |
0.940 (47/50) |
0.792 (38/48) |
0.867 (85/98) |
0.825 (47/57) |
0.927 (38/41) |
| Radiomic nomogram of standard-dose CT |
0.909 (0.946–0.972) |
0.840 (42/50) |
0.896 (43/48) |
0.867 (85/98) |
0.894 (42/47) |
0.843 (43/51) |
| Lung-RADS | 0.761 (0.685–0.837) |
0.960 (48/50) |
0.562 (27/48) |
0.765 (75/98) |
0.696 (48/69) |
0.931 (27/29) |
| Validation cohort | ||||||
| Radiomic signature of low-dose CT |
0.976 (0.944–1.000) |
0.864 (19/22) |
0.857 (18/21) |
0.860 (37/43) |
0.864 (19/22) |
0.857 (18/21) |
| Radiomic nomogram of low-dose CT |
0.976 (0.941–1.000) |
0.909 (20/22) |
0.905 (19/21) |
0.907 (39/43) |
0.909 (20/22) |
0.905 (19/21) |
| Radiomic signature of standard-dose CT |
0.985 (0.960–1.000) |
0.955 (21/22) |
0.905 (19/21) |
0.930 (40/43) |
0.913 (21/23) |
0.950 (19/20) |
| Radiomic nomogram of standard-dose CT |
0.987 (0.965–1.000) |
0.909 (20/22) |
0.952 (20/21) |
0.930 (40/43) |
0.952 (20/21) |
0.909 (20/22) |
| Lung-RADS | 0.833 (0.730–0.937) |
1.000 (22/22) |
0.667 (14/21) |
0.837 (36/43) |
0.759 (22/29) |
1.000 (14/14) |
Unless otherwise specified, numbers in the parentheses were used to calculate percentages. Lung-RADS, Lung CT Screening Reporting and Data System; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.